Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.34 |
| ▸ | NR1I3 | Q14994 | 5/20 | 0.33 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.33 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.33 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885024 | 0.95 | SIRT2 (0.33) | SIRT2PFKFB2PFKFB1PFKFB3HPGD | |
| SCHEMBL2885026 | 0.95 | SIRT2 (0.33) | SIRT2PFKFB2PFKFB1PFKFB3HPGD | |
| SCHEMBL13051954 | 0.88 | NR1I3 (0.34) | NR1I3HPGDNPC1CYP1A2CYP2D6 | |
| SCHEMBL10096262 | 0.87 | MEN1 (0.38) | HPGDNPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12994898 | 0.87 | PDE1C (0.30) | — | |
| SCHEMBL12107246 | 0.87 | RORC (0.37) | SIRT2NR1I3HPGDNPC1CYP1A2 | |
| SCHEMBL983202 | 0.87 | HPGD (0.35) | SIRT2NR1I3HPGDNPC1CYP1A2 | |
| SCHEMBL10096724 | 0.86 | ALDH1A1 (0.35) | HPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL981985 | 0.86 | SMN1; SMN2 (0.47) | HPGDNPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12994895 | 0.86 | CYP1A2 (0.33) | CYP1A2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | SIRT2 2394/4885NR1I3 449/4885PFKFB2 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.